nvco
ǻЪѹ
¢

 

ԡ͡Ǣͷͧҹ

1. ͧ-ͧȼԵѤչ

2.ҷ¢ͧҴѤչҤ

3.˹ҡԨ·ҧչԤͧѤչʹ췴ͧ

4.ѤչͧѹõԴ HPV

5.çͺԧԺѵԡ üԵСäǺسҾѤչҡѴ˭ ѹ 11-22 Զع¹ 2555

6.A word a day “A.E.C. – Asian Economic Community”

 

 

 

 

ͧ-ͧȼԵѤչ

ѭ ԾԷҤسԨ

йդö㹡üԵѤչ鹹§ 2 Դ Ѥչͧѹͧѡʺ ͧ˹ Ѥչիը ͧѹѳä  ˹§ҹ͢´ҹѤչ˹§ҹǢͧբ͵ŧѹзӡԨ¾ѲмԵѤչͧҡ ѡҾüԵѤչҵðҹҡ ѧҡٻͧçõҧ 觪ҵԴҹѤչСȵҸó 2554 ǺѨغѹպҧç÷ԹõἹ˹ ͻѺٻẺôԹ繡ҧ͡ѺçҹԵѤչҡҧ 駹ͧ˵»С÷Ӥѭ ѺԹʹѺʹعҡӹѡҳ  ؤҡըӹǹӡѴѡҾ§㹡ôԹҹ  õѴԹŧعԹô˵ؼ ͫѤչ١ŧعԵͧ çŧعҨ稡  ˵ؼŵҧ ҹռþѲҴҹüԵѤչͧҪҡһ աõѴԹҧѴਹ ŧ㹡ءҹçҧ鹰ҹ ෤ ѵҡѧ ѡҾͧؤҡ żԵ ͹Ӥѭ աŧعҧԧѧкèѴä§ҧ

ҡ֡Ҵ٧ҹҹüԵѤչͧѷ ⹿ Ƚ кѷ CDBIO ҸóѰЪҪչ ͹ҤҹҾҨش͹ѹͧ 2 㨷мԵѤչͧ Ф㹡Ԩ¾ѲѤչդسҾҵðҹҡ ö˹¼Եѳ㹵Ҵš ͡ҡѧӡâµҴ㹻ȵҧ š ǺѺŧع¡üԵѤչҳ§͡ѺͧâͧҴ  蹪Ѵ ѷͧȨչ鹾ѲҡüԵѤչԴǡ͹ «෤աüԵҡҡѰԡ  ؤҡѺö·ʹ෤§ 2   ǾѲҡüԵºؤҡâͧѷʺ ö˹ѤչҴ㹻 лȵҧ 3     þѲҡüԵѤչͧȨչ֧з繵ҧ лդоѲ෤աüԵѤչͧѹͧѡʺ §ҹҹ 5 ѨغѹѧԵ෤մ ѧͧҨмԵѤչͧ෤չ зȨչ繤稢ͧԵѳѤչͧѹäعѢ (Rabies vaccine) ¡üԵѤչѤչͧѡʺ ෤§ ö˹¼ԵѳСþѲ 3 ǡѹ 

 

 

 

繷ʹաС˹觤 ؤҡ÷ӡԨ¾ѲмԵѤչǹ֡㹻ȷ ͡ҡӹѡҹС(.) ҸóѰЪҪչ觨ѺѺͧ WHO Prequalification ͻշҹ 㹢з .ͧҹѺͧ WHO Prequalification 4 ա͹ ѧѤչԵ鹹Ө˹㹵Ҵҧ

 

 

Ѻ

 

 

 

ҷ¢ͧҴѤչҤ

Ȩվó Өԧ

25 շҹ 觢ѹصˡҹѤչҧ աŧعӹǹ 駷ҧҹԨ¾Ѳ ÷ͺҧԹԡ ʹѺاçҧ鹰ҹջԷҾФѹҡ觢  ѺѵҡԺⵢͧصˡѤչšҧǴ Ѻҡ 2005 -2008 ҴѤչⵢҡͧ 㹻 2008-2009 Ѥչǹ觡õҴҡҼԵѳ Դ 16 Ť 22. 1 ҹ­Ѱ ФҴҨԺѵ 5 աһբҧ˹ ŤͧҴѤչѨغѹҳ 20 ѹҹ­Ѱ ФҴ㹻 .. 2017 Ժ⵶֧ 32.21 ѹҹ­Ѱ 觡ŧع㹡üԵѤչǹ˭ ǹҨҡ͡Ҥ· ҧá ҡǶ֧ᶺ ѧѲѡҾͧͧö觢ѹ㹵Ҵš »ȴ¡ѹ Ȩչ繻˹觷ѡҾѹѺ ͧüԵѤչͻ͹ҴҤ ͧҡռԵѤչ 30 ѤչԵҳ 40 Դ ͺ 20 ä 㹻 2009 ѵҡԺⵢͧáԨѤչ 15  Ť͡ӴѺ 5 ͧš (Ťһҳ 77 ѹҹ­Ѱ) ҧѷѡ˭ China National Biotech Group (CNBG) ͡Ѥչҡش֧ 800 ҹʵͻ ҧá Ѻ͡ʡþѲҧҹҹѤչ㹻Ȩչ   سҾͧѤչѧöҧ§ 觢ѹѺѷҵԢҴ˭ ͧҡҨԹ㴷Ե㹻Ȩչ   ֧Ҥҵӡһ ѡ١ͧդسҾ 駼ԵѳѤչҨͧա˹ҧͶ ФѺȤ  ͡ҡ ѵ㹡Ԩ¾ѲСüԵѤչǹ˭ ١Ե෤Ẻ ѺʶҹóФͧ㹻Ѩغѹ

ѺԹ ǹ觡õҴҹѤչҤѰ٧֧ 130 ҹ­ Ҥ͡ 140 ҹ­  ԹպѷԵѤչ㹻 ҡ 10 ѷ Bharat Biotech, Shantha Biotech, Bilogical E,  Zydus Cadial, Serum Institute of  India, Haffkine Biophama 繵 кѷҵ  Glaxo SmithKline,  Sanofi  Aventis Novatis  ҧáԹ 繵ͧçҧ鹰ҹмǪҭʹšüԵջԷҾ лʹҡ ͡ҡԹ¤ӤѭѺҧѹԵǹѹѲҧҹԨ´ҹѤչԴҡҡ 觷駨չ Թ¨繵ͧѲҡʹѺʹعʶҺѹԨصˡѤչͧͧ¡дѺþѲҧҹҹѤչͧ  ö觢ѹѺҵԵѹ͹Ҥ

 

ҧʴѵҡԭԺⵢͧˡѤչšҧ 2005 - 2012

 

ԧǡѹ Ѵ㹡ȷѵҡԭԺⵢͧҴѤչ͹ҧ٧ ͧҡժ§ҹ෤ժҾмԵѳ դҹçҧ鹰ҹ СͺѺաâ¡ŧعçҹԵѤչ㹻ȨչԹ  зáԨѤչա觢ѹСŧع٧ 觼ѷѤչºѷԧ觵ͧԴŧ ҧ觵ͧǺѷҫ͡Ԩͤʹ ҧ ѷ SingVax ͵駻 2004 觵㹻 2009 ǺԨáѺѷ Inviragen  繵

֧Ѩغѹ»Ҥ»ʹѹҼԵѤչ͡þ觾ҵͧ оѲҧҹѤչդҡ ѧ ѰѹŧعçҹԵѤչµͧ ǧҤͨҡҧҵ СͺѺ˹ºŧعͧѷҧҵ Ѥչ§͹Ҥ ԴҷաС˹觷Դ鹡ѺҴѤչҤ ٭µҴѺѷҢҵԷѧԭԺҧǴ ҧá ŧعصˡѤչͧҧҵ੾Тҹ ҡԨóͧɰԨǨо ŧعѧǡԴèҧҹ  þѲҷѾҡ ͧѺѵ/Էҡ  ʹö·ʹ෤ 繵

㹻Ѩغѹ ʡ觢ѹͧصˡѤչš ǹ繻ѨӤѭѡѹҤ¤ҧԭԺ㹻Ȣͧ ѹҧͨҡءҤǹ ҤѰ Ҥ͡ʶҺѹ֡ҷҧ кǹõ鹹(Upstream) ֧¹(Downstream) ѹ Ԩ¾Ѳ Ե Сѹ ФǺسҾСªҡѤչ Ŵþ觾Թع෤ըҡѷҧҵ ҡ蹹 صˡѤչᶺ¨ö׹ҵͧ¤ ҧԧ

Ѻ

 

 

 

˹ҡԨ·ҧԹԡ

ͧѤչʹ췴ͧ㹻

ó

Ѻʹͼҹͧ A Bangkok Surprise 觡Ƕ֧÷ͺѤչʹ㹻 ੾çԨѤչʹ췴ͧ “پ-е” з 3 (RV144) Thai trial  㹵͹ ѧçԨ·ͧҡç RV144 ֡ҡ䡡÷ӧҹͧѤչͧѧ  Ѻ ֧͹ʹçԨѤչʹ췴ͧա 2 ç Թ֡㹻

çԨáԹ͹¹ҹ ç Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-Uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: “Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults” ¡ “RV305” 繡÷ͺз 2 ѵػʧ ͻԹšзáе鹫ӷ駪ǧ (Late boosting) ͡õͺʹͧͧԤѹẺù mucosat Systemic compartments ͧѺѤչç RV144 դԹԡԺѵԡԨ㹾鹷ѺԴͺͧçҺźҧاçҺžҹͧ ѧѴź

ç RV305 Ѥçá 160 Ѥ÷ç RV144 Ѥչú ͹ 0, 1, 3 6 ͹ 0 1 Ѥչپ鹤 ALVAC ǹ͹ 3 6 ѤչپСе ALVAC-HIV AIDSVAXB/E ӴѺ ÷ͺ㹤駹մе ѻ 0 24 Ѥչ 3 ٵ 1) ALVAC-HIV + AIDSVAXB/E ALVAC-HIV placebo + AIDSVAX B/E placebo 2) AIDSVAX B/E AIDSVAX B/E placebo 3) ALVAC-HIV ALVAC-HIV placebo աõԴһҳ 1 ҷ 1 դ

 

 

çôѧԴҡͧ͢˹§ҹҤǹеҧ Ǻä  зǧҸóآ ٹ췴ͺѤչ Ǫʵࢵ͹ ԷԴ ʶҺѹԨԷʵᾷ (AFRIMS) ŧóԷ ҡҪҴ çԨͪբͧͧѾѰ ͧ͹š ѷ Sanofi Pasteur кѷ Global Solutions for Infectious Diseases U.S. Army Medical Research and Materiel Command ʹѺʹعԨ չᾷ ġ çسزԴҹǪͧѹ Ǻä 繼Ԩѡ شç RV305 ҧἹ ͹Ҥ ..2556

 

 

ǹç÷ͧ ç÷ժ RV306 觢йѧҧþԨó͹ѵçҧԨ¨ҡСþԨóҴҹ¸㹤 ѵػʧͻԹšзҡáе鹫ӷ駪ǧ (Early boosting) ͡õͺʹͧͧԤѹͧҧ·Ẻù mucosat Systemic compartments Ѥ÷ѧԴӹǹҳҳ 460 ʶҹ軯ԺѵԡԨٹ췴ͺѤչ Ǫʵࢵ͹ ԷԴ ʶҺѹԨԷʵآҾ Է§ ʶҺѹԨԷʵᾷý ٹԨäʹ ҡҪҴ Ԩѡͧç
..ó ԵطԸ Ǫʵࢵ͹ ԷԴū觤ҴҨԨ͹áҤ 2555

ç֡Ԩ·ͧ 繡Ӥѭա˹觢ͧ 㹡Ԩ¾ѲѤչͧѹäʹѺ˹§ҹҡҹһ ѧǷҧ㹡þѲѤչʹʷͧ 觨¢ʶҺѹѤչ觪ҵԡйʹͤ˹Ңͧç÷ͧ͡ʵ仴 ʶҺѹѤչ觪ҵԢ繡ѧԨѤ÷ءҹТԨ´Թ´յʹç

Ѻ

 

 

 

 

 

ѤչͧѹõԴ HPV

ɳ Ҫ

移ҡ١秪Դءʵշš ռлջҳ 500,000 »ҳ 275,000 ͻ 㹨ӹǹ繼㹻ȡѧѲһҳ 85 Ѻ移ҡ١˵ءõѹѺ˹ͧºѺ秪Դ 㹼˭ԧ ռҳ 6,000 – 10,000  ªԵҳ 3,166 ͻ м٧  

 

Human papillomavirus (HPV)

Ҿҡ  http://www.bloggang.com

 

˵ѡͧ移ҡ١ ԴҡõԴ Human papilloma virus  HPV  ҡ 100 ¾ѹ ¾ѹ 16 18 ˵آͧ移ҡ١ҳ 70
ҡ١öͧѹ¡õǨѴͧҧ͵С͹ Ը (Pap smear) 繡ûͧѹäẺص (Secondary prevention) Ը˹ աԡԺ ѧ㹻ѨغѹͺͧõǨѴͧࡳѧдѺ ͧҡҴѺТͨӡѴ »С ǹѺѤչͧѹõԴ HPV Ըա ·繡ѺѹҡѤչ㹡ûͧѹä繡ûͧѹẺ (Primary prevention) ջԷԼ Фع٧ ʹҶ֧ͧѺѤչ Ѥչը˹㹻Ѩغѹ 2 Դ    Դͧѹ HPV  ¾ѹ 16   18  Դͧѹ¾ѹ 6, 11, 16 18  ҧáѤչöͧѹä 100 繵 ֧ͧǨѴͧҧ

 

ѡɳСԴ移ҡ١

Ҿҡ   http://www.all-magazine.com

 

㹻ѨغѹչѤչͧѹõԴ HPV ԡá¡ 30 ҧáѧբͶ§ҧҧҧ㹻ȡѧѲ»㹴ҹͧùѤչçҧԤѹäͧҡѤչҤᾧ Ѻ㹻ѨغѹѤչ˹Ҥ͡ 2,000 ҷ ͧմ 3 6,000 ҷ зǧҸóآʹաéմѤչ˭ԧ 12 ջҳ 400,000 ͻ ҤѤչԹ 500 ҷ ҳͻջҳ 510 ҹҷ  ѧդѧҤҴѧѧҤҵش ѷҨŴҤѤչա ҧ ©մѤչ˭ԧ  13 ء лҳ 300,000 ѰöͧҤѤչ 500 ҷ ջЪҡҡ ֧դ㹡õͧҤŴŧա

ѧҧһ¤صҤҪҨ觷͡ʷлͧѹûªԵ蹤͹Ҥ 㹻Ѩغѹ͹ءҧԤѹä СѤչ觪ҵ оԨóҤҹҧͧùѤչԴҺèçҧԤ鹡ѹä㹻

Ѻ

 

 

çͺԧԺѵԡ
üԵСäǺسҾѤչҡѴ˭ ѹ 11-22 Զع¹ 2555

þѲѡҾؤҡǹӤѭ㹡þѲҧҹҹѤչͧҧҡ 駹ͧҡѨغѹѡҾ㹡üԵѤչͧŴŧҧѴСͺѺ෤մҹþѲмԵѤչԴ ǹդҡйѺѹդѺ͹ҡ ֧繷ȨеͧǷѹ෤շդѹ 㹢ǡѹеͧѲ ҧؤҡ÷ѡҾͧѺ¹ŧ öѲö㹡觢ѹѺҹһ͹Ҥա ҡӤѭѧ ʶҺѹѤչ觪ҵԨ֧աçùͧ㹡þѲѡҾؤҡôҹѤչѴçþѲҺؤҡôҹѤչҧк çáդ͡ѺѪʵ Է¢͹ ˹§ҹ͢·Ǣͧ㹡èѴѡٵáý֡ͺ 㹡üԵСäǺسҾѤչҡѴ˭ 觨Ѵѹ 11-21 Զع¹ 2555 Է¢͹

ͺ㹤駹 ͺѺ зѡ㹡ûԺѵǡѺкǹüԵФǺسҾѤչѴ˭誹Դ͹ķ(Live Attenuated) 㹷ء鹵͹ Էҡ÷ǹդǪҭҡҡҢ Сͺ ҹԷ ҹԤѹԷ ҹԷš ҹüԵдѺ鹹Ө֧¹ дҹäǺӡѺسҾѤչ

ҡôԹþ ˹§ҹʹ觺ؤҡѧѴӹǹ 35 ˹§ҹ觺ؤҡý֡ͺǹ˹§ҹդӤѭǧáþѲѤչͧ Сͺ ͧѪ ٹ෤ժҾҹᾷҸóآ Էʵᾷ ʶҺѹԨ¨ó ʶҺѹԨԷʵᾷ ѷ ๷- ѷ ͧѪ--
ѵ Էʵ ԷŻҡ Է෤վШҸ ʶҺѹѤչ觪ҵդѧҨҹਵ㹡þѲҺؤҡôҹѤչ ǹҹѤչͧöԹ˹ҵҧش

 

öҾ˹ҤäѪʵ

 

Դͺ
..ا ͧ


Ըͺͧ֡¤դѪʵ
мӹ¡ʶҺѹѤչ觪ҵ

 

зӧҹ .ѭ ԾԷҤسԨ
ٻѺԷҡ.Ѫ ٶеС

 

ͺҤ

 

Virus ҡѡ (SPF egg)

 

鹵͹÷ Formulation Ѥչ

 

鹵͹úèСûԴҢǴѤչ

 

õԴҡǴèѤչ

 

ǴèѤչҧҡͺ

 

ӹ¡ʶҺѹѤչ觪ҵ
ͺСȹºѵͺ

 

ӹ¡ʶҺѹѤչ觪ҵͺͧ֡
ѺԴͺèѴͺ ..õ ࢵԷѡǧ

 

Ѻ

 

 

A word a day
“A.E.C. – Asian Economic Community”

Թ ըʹ

繷Һѹ 㹻վطѡҪ 2558 㹡Ҫԡ¹ջҡó       ӤѭԡѵʵͧҤ蹤 ЪҤɰԨ¹ Asian Economic Community – A.E.C. Ѻ繡¡дѺͧ͢¹Ե㹡ҧЪҤͧ͢þѲһ A word a day ѺʹͷҢͤ Asian Economic Community ԧʵ   ʹ㨴ѧ

  1. Asian 繤ӹ ¶֧ "inhabitant of Asia” ҡѾҨҡҡաҳ Ασία “to go out, to rise” (͡, ¡٧) ҳѡ㹺Ժ (context) ¶֧ǧҷԵ ѧ Asian ֧¶֧ "the people who lives in the land of the sunrise."
  2. Economic 繤ɳ Ҩҡӹ Economy ҡ㹾ҹءѧ繤áǻ .. 1530 շҨҡеԹҳ “oeconomia” "household management" (èѴ㹤͹) 㹻Ѩغѹդ¡ҧ (Generalization) 㹤 “ҹѹǡѺüԵ è˹¨ᨡ ú觵ҧ ͧ”
  3. Community 繤ӹ Ҩҡҽҳȵɷ 14 comunity” ¶֧public, general, or shared by all or many” Ѩغѹ㹤¢ͧǺ觷ѡɳǡѹ ըشʧѹ

          ѧ㹤駹餧繻ªѺҹҡ ѹ詺Ѻ˹ҤѺ

 

 

Ҿҡ http://damansky-world.exteen.com/20120725/home-bias-aec

 

Ѻ

ѹѺا : 2555 .. 18